West Pharmaceutical Services Inc. (WST) Holdings Reduced by Bessemer Group Inc.
Bessemer Group Inc. lowered its position in West Pharmaceutical Services Inc. (NYSE:WST) by 43.5% in the fourth quarter, Holdings Channel reports. The fund owned 7,064 shares of the medical instruments supplier’s stock after selling 5,446 shares during the quarter. Bessemer Group Inc.’s holdings in West Pharmaceutical Services were worth $697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently made changes to their positions in the company. Citigroup Inc. lifted its stake in West Pharmaceutical Services by 95.1% in the second quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 765 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in West Pharmaceutical Services in the second quarter valued at $201,000. Grandfield & Dodd LLC acquired a new stake in West Pharmaceutical Services in the third quarter valued at $201,000. Private Advisor Group LLC acquired a new stake in West Pharmaceutical Services in the third quarter valued at $202,000. Finally, Tiedemann Wealth Management LLC acquired a new stake in West Pharmaceutical Services in the third quarter valued at $207,000. Hedge funds and other institutional investors own 92.69% of the company’s stock.
WST has been the subject of a number of recent analyst reports. Bank of America cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target for the company. in a research note on Tuesday, October 17th. Wells Fargo & Co increased their price target on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Zacks Investment Research cut shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Finally, Goldman Sachs Group initiated coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $108.17.
West Pharmaceutical Services Inc. (WST) opened at $91.25 on Friday. The firm has a market cap of $6,713.95, a PE ratio of 36.35, a PEG ratio of 1.92 and a beta of 1.04. West Pharmaceutical Services Inc. has a 1 year low of $77.97 and a 1 year high of $103.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Thursday, January 18th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. The ex-dividend date was Wednesday, January 17th. West Pharmaceutical Services’s payout ratio is presently 22.31%.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.